Aurobindo Pharma Performance
- Today's Low
- ₹1,477
- Today's High
- ₹1,511
- 52 Week Low
- ₹1,016
- 52 Week High
- ₹1,550
- Open Price₹1,498
- Previous Close₹1,498
- Volume1,718,469
- 50 DMA₹1,424.21
- 100 DMA₹1,362.22
- 200 DMA₹1,291.07
Aurobindo Pharma Chart
Investment Returns
- Over 1 Month -3.54%
- Over 3 Month + 15.53%
- Over 6 Month + 21.78%
- Over 1 Year + 35.97%
Smart Investing Starts Here Start SIP with Aurobindo Pharma for Steady Growth!
Aurobindo Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 23.2
- PEG Ratio
- 3.3
- Market Cap Cr
- 86,650
- P/B Ratio
- 2.3
- Average True Range
- 37.66
- EPS
- 61.09
- Dividend Yield
- 0.3
- MACD Signal
- 2.94
- RSI
- 58.58
- MFI
- 66.75
Latest Stock News Updates
Aurobindo Pharma on Monday said its arm Aurobindo Pharma USA, Inc has received approval from the US Federal Trade Commission (FTC) for its USD 250 million acquisition of Lannett Company LLC. The transaction, valued at USD 250 million on a cash-free, debt-free basis and inclusive of normalised working capital, is expected to close before the end of this month, Aurobindo Pharma said in a regulatory filing. Lannett, a Pennsylvania-based generic pharmaceutical company, specialises in the development and commercialisation of a diversified portfolio of complex, non-opioid controlled substances, the filing said. The acquisition will significantly expand Aurobindo USA's product offering in this segment while adding a US-based manufacturing facility to its network, it added. "This acquisition represents a highly compelling strategic and financial opportunity for Aurobindo USA. It accelerates our revenue growth, strengthens our US-based manufacturing capabilities, and enhances our position i
- Business Standard
- 13 hours 30 minutes ago
Here is what the charts say about the shares of Aurobindo Pharma, Bharat Electronics and Trent
- Business Line
- 2 days 3 hours ago
Aurobindo Pharma received necessary approval from the US Federal Trade Commission (FTC) for the acquisition of the Lannett business.
- Business Standard
- 3 days 13 hours ago
Aurobindo Pharma Financials
Aurobindo Pharma Technicals
EMA & SMA
- Bearish Moving Average 0
- Bullish Moving Average 16
- 20 Day
- ₹1,453.60
- 50 Day
- ₹1,424.20
- 100 Day
- ₹1,362.20
- 200 Day
- ₹1,291.10
Resistance and Support
- R3 1,544.27
- R2 1,527.63
- R1 1,509.77
- S1 1,475.27
- S2 1,458.63
- S3 1,440.77
Aurobindo Pharma Corporate Actions - Bonus, Splits, Dividends
Aurobindo Pharma F&O
About Aurobindo Pharma
- NSE Symbol
- AUROPHARMA
- BSE Symbol
- 524804
- ISIN
- INE406A01037
Similar Stocks to Aurobindo Pharma
Popular Stocks
Aurobindo Pharma FAQs
Aurobindo Pharma share price is ₹1,491 As on 23 June, 2026 | 01:16
The Market Cap of Aurobindo Pharma is ₹86649.8 Cr As on 23 June, 2026 | 01:16
The P/E ratio of Aurobindo Pharma is 23.2 As on 23 June, 2026 | 01:16
The PB ratio of Aurobindo Pharma is 2.3 As on 23 June, 2026 | 01:16
Aurobindo Pharma has an operating revenue of Rs.24,010.31 Cr. on a trailing 12-month basis. An annual revenue growth of 8% is good, Pre-tax margin of 30% is great. Many brokers and analysts have recommended 'Buy' on the stock.
Aurobindo Pharma Ltd. has declared 40 dividends since May 10, 2000.
The stock price CAGR of Aurobindo Pharma for 10 Years is 30%, 5 Years is 0%, 3 Years is -3%, 1 Year is -25%.
Aurobindo Pharma has an ROE of 24% which is exceptional.
Aurobindo Pharma has a reasonable debt to equity of 1%, which signals a healthy balance sheet.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.